Approval · Notice of Compliance 24005 · 2020
TECENTRIQ: Notice of Compliance 24005
Issued August 7, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24005
- Date
- August 7, 2020
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: Tecentriq in combination with bevacizumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TECENTRIQ | Not yet assigned | — |
Medicinal ingredients
- ATEZOLIZUMAB 1,200 MG per 20ML
- ATEZOLIZUMAB 840 MG per 14ML